Endpoint surrogacy in oncology Phase 3 randomised controlled trials

Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint—instead of overall survival—would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jianrong, Pilar, Meagan R., Wang, Xiaofei, Liu, Jingxia, Pang, Herbert, Brownson, Ross C., Colditz, Graham A., Liang, Wenhua, He, Jianxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403397/
https://www.ncbi.nlm.nih.gov/pubmed/32451466
http://dx.doi.org/10.1038/s41416-020-0896-5
_version_ 1783566932797030400
author Zhang, Jianrong
Pilar, Meagan R.
Wang, Xiaofei
Liu, Jingxia
Pang, Herbert
Brownson, Ross C.
Colditz, Graham A.
Liang, Wenhua
He, Jianxing
author_facet Zhang, Jianrong
Pilar, Meagan R.
Wang, Xiaofei
Liu, Jingxia
Pang, Herbert
Brownson, Ross C.
Colditz, Graham A.
Liang, Wenhua
He, Jianxing
author_sort Zhang, Jianrong
collection PubMed
description Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint—instead of overall survival—would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs.
format Online
Article
Text
id pubmed-7403397
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-74033972021-05-26 Endpoint surrogacy in oncology Phase 3 randomised controlled trials Zhang, Jianrong Pilar, Meagan R. Wang, Xiaofei Liu, Jingxia Pang, Herbert Brownson, Ross C. Colditz, Graham A. Liang, Wenhua He, Jianxing Br J Cancer Editorial Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint—instead of overall survival—would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs. Nature Publishing Group UK 2020-05-26 2020-08-04 /pmc/articles/PMC7403397/ /pubmed/32451466 http://dx.doi.org/10.1038/s41416-020-0896-5 Text en © Cancer Research UK 2020 https://creativecommons.org/licenses/by/4.0/Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Editorial
Zhang, Jianrong
Pilar, Meagan R.
Wang, Xiaofei
Liu, Jingxia
Pang, Herbert
Brownson, Ross C.
Colditz, Graham A.
Liang, Wenhua
He, Jianxing
Endpoint surrogacy in oncology Phase 3 randomised controlled trials
title Endpoint surrogacy in oncology Phase 3 randomised controlled trials
title_full Endpoint surrogacy in oncology Phase 3 randomised controlled trials
title_fullStr Endpoint surrogacy in oncology Phase 3 randomised controlled trials
title_full_unstemmed Endpoint surrogacy in oncology Phase 3 randomised controlled trials
title_short Endpoint surrogacy in oncology Phase 3 randomised controlled trials
title_sort endpoint surrogacy in oncology phase 3 randomised controlled trials
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403397/
https://www.ncbi.nlm.nih.gov/pubmed/32451466
http://dx.doi.org/10.1038/s41416-020-0896-5
work_keys_str_mv AT zhangjianrong endpointsurrogacyinoncologyphase3randomisedcontrolledtrials
AT pilarmeaganr endpointsurrogacyinoncologyphase3randomisedcontrolledtrials
AT wangxiaofei endpointsurrogacyinoncologyphase3randomisedcontrolledtrials
AT liujingxia endpointsurrogacyinoncologyphase3randomisedcontrolledtrials
AT pangherbert endpointsurrogacyinoncologyphase3randomisedcontrolledtrials
AT brownsonrossc endpointsurrogacyinoncologyphase3randomisedcontrolledtrials
AT colditzgrahama endpointsurrogacyinoncologyphase3randomisedcontrolledtrials
AT liangwenhua endpointsurrogacyinoncologyphase3randomisedcontrolledtrials
AT hejianxing endpointsurrogacyinoncologyphase3randomisedcontrolledtrials

Ejemplares similares